Ensuring Pathways to Innovative Cures Act of 2025 aims to equalize negotiation periods for small-molecule and biologic drugs.
The Ensuring Pathways to Innovative Cures Act of 2025, also known as the EPIC Act of 2025, amends title XI of the Social Security Act to adjust the negotiation period for drug prices under the Drug Price Negotiation Program. Specifically, it modifies the eligibility criteria for drugs to be included in the negotiation process. For the initial price applicability years of 2026 and 2027, drugs must have been approved at least seven years prior. Starting from the initial price applicability year of 2028, drugs must have been approved at least eleven years prior.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.